SPRENT Trial (Silodosin for Pediatric Renal Stone ExpulsioN Trial)

Safety and efficacy of Silodosin as medical expulsive therapy after shock wave lithotripsy in paediatric patients with renal stones: a prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202503893791588

Enrollment

Registered

2025-03-10

Start date

2019-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases Kidney Disease

Interventions

Silodosin treatment after shockwave lithotripsy session

Placebo group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study included paediatric patients under 18 years old with newly diagnosed single radiopaque renal pelvic stone (< 2 cm) in maximum diameter and eligible for SWL.

Exclusion criteria

Exclusion criteria: We excluded patients with a solitary kidney, congenital or acquired renal or ureteral abnormalities, significant hydronephrosis (as per Onen’s criteria), presence of a JJ stent, active UTIs, or impaired renal function (eGFR < 60 mL/min/1.73 m²), dense hard stones with Hounsfield unit (HU)?1000 in CT films or with history of bleeding diathesis.

Design outcomes

Primary

Measure	Time frame
stone expulsion time for small stone fragments, comparing Silodosin to standard care following SWL for renal pelvic stones.	—

Secondary

Measure	Time frame
pain scores, analgesic usage, stone expulsion time, one session SFR, duration of haematuria, and adverse events.	—

Countries

Egypt

Contacts

Public ContactMohamed ElKholefy

Assistant Lecturer and Registrar of Urology

me7325217@gmail.com00201004446452

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026